Company / Operating Income
Atea Pharmaceuticals, Inc. Operating Income History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$130.7M
FY2022
5-year range
-$130.7M / -$9.5M
FY2020-FY2022
Trend
-794.4%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income changed -794% YoY in FY2022, a notable deviation from the 2-year average annual change of -424%.
Based on SEC 10-K filings.
-$131M in FY2022.
Declined from -$9M to -$131M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, operating income decreased 794.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 10.30 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$130.7M | -794.4% |
| FY2021 | -$14.6M | -54.1% |
| FY2020 | -$9.5M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026